Hormonal
Once-weekly subcutaneous semaglutide (up to 2.4 mg) significantly reduces body weight, BMI, and waist circumference in adults with obesity or overweight compared to placebo, with effects demonstrating a dose-response relationship.
For adults with obesity or overweight, once-weekly semaglutide (titrated up to 2.4 mg) combined with lifestyle changes is a highly effective medical intervention for significant weight loss, outperforming lifestyle changes alone. While gastrointestinal side effects like nausea are common, they are usually manageable and do not typically lead to stopping treatment.
Compared with placebo, semaglutide was more effective in reducing body weight (WMD: 5.52 kg, 95% CI:-7.35kg, -5.78kg, P <0.00001) and percentage of body weight by 10.88% (95% CI:-12.98%, -8.79%).
Why this rating
Systematic review and meta-analysis of 9 RCTs with 5324 patients.
Source
Effects of once-weekly semaglutide in obese/overweight patients: A systematic review and meta-analysis
Mengjun Wang et al. · Research Square · 2022
DOI 10.21203/rs.3.rs-2346356/v1
More from this paper
- Once-weekly semaglutide improves cardiometabolic markers including HbA1c, fasting plasma glucose, blood pressure, and lipid profiles in overweight/obese patients, independent of or alongside weight loss.Strong
- Semaglutide treatment is associated with a significantly higher incidence of gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) compared to placebo, though these are mostly mild to moderate.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →